| Schedule of Segment Reporting |
The operating financial results of the Company’s R&D segment for the three and nine months ended September 30, 2026 and 2025 are as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Revenue | $ | 1,899 | | | $ | 795 | | | $ | 4,972 | | | $ | 3,150 | | | Less: Significant segment expenses | | | | | | | | | Personnel-related expenses | 6,542 | | | 4,922 | | | 18,627 | | | 15,701 | | | Clinical and preclinical expenses | 5,356 | | | 4,313 | | | 15,056 | | | 13,502 | | | Facilities-related and overhead | 1,820 | | | 2,584 | | | 5,370 | | | 6,582 | | | Professional and consulting fees | 1,365 | | | 2,204 | | | 4,229 | | | 5,390 | | | Corporate expenses | 603 | | | 297 | | | 1,354 | | | 1,334 | | | | | | | | | | | Travel and entertainment | 242 | | | 126 | | | 816 | | | 420 | | | Plus: Other segment (loss) income | (14,927) | | | (1,448) | | | (40,337) | | | (340) | | | Segment net loss | $ | (28,956) | | | $ | (15,099) | | | $ | (80,817) | | | $ | (40,119) | |
|